肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

Trizell制药宣布进行干扰素α-2b基因疗法治疗恶性胸膜间皮瘤的III期关键研究

2019-03-21 不详 网络

胸膜间皮瘤干扰素α-2bTR002
关注

Trizell制药公司近日宣布，它已开始对其新型基因疗法TR002（一种腺病毒介导的干扰素α2b）进行III期研究，该研究用于恶性胸膜间皮瘤（MPM）患者，这些患者经一线标准治疗后失败。干扰素是人体用于对抗癌症的天然蛋白质，TR002治疗的目的是触发干扰素的多效抗肿瘤作用，随后则使用吉西他滨进行化疗。

Trizell制药公司近日宣布，它已开始对其新型基因疗法TR002（一种腺病毒介导的干扰素α2b）进行III期研究，该研究用于恶性胸膜间皮瘤（MPM）患者，这些患者经一线标准治疗后失败。干扰素是人体用于对抗癌症的天然蛋白质，TR002治疗的目的是触发干扰素的多效抗肿瘤作用，随后则使用吉西他滨进行化疗。

恶性胸膜间皮瘤是一种侵袭性和破坏性的癌症形式，影响肺的外（胸膜）膜。这种疾病通常是通过吸入石棉纤维引起的，石棉纤维从胸腔缓慢地从肺泡到肺外表面，诱发癌症。职业或环境中的石棉与矿物纤维的暴露和MPM发展之间存在明显的关联。


原始出处：

http://www.firstwordpharma.com/node/1630604#axzz5ioDx2kLe

本文系梅斯医学（MedSci）原创编译整理，转载需授权!

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1666277, encodeId=67d716662e711, content=<a href='/topic/show?id=bbaf8420118' target=_blank style='color:#2F92EE;'>#胸膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84201, encryptionId=bbaf8420118, topicName=胸膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fbc026056217, createdName=lifestar, createdTime=Mon Jan 20 23:26:00 CST 2020, time=2020-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916090, encodeId=a14b19160905f, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Thu Feb 13 14:26:00 CST 2020, time=2020-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1579809, encodeId=f58d15e98091f, content=<a href='/topic/show?id=6db59e28738' target=_blank style='color:#2F92EE;'>#间皮瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97287, encryptionId=6db59e28738, topicName=间皮瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d61a16562641, createdName=1249884fm92暂无昵称, createdTime=Sat Mar 23 12:26:00 CST 2019, time=2019-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594579, encodeId=eaf815945e9cc, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Mar 23 12:26:00 CST 2019, time=2019-03-23, status=1, ipAttribution=)]
    2020-01-20 lifestar

    #胸膜#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1666277, encodeId=67d716662e711, content=<a href='/topic/show?id=bbaf8420118' target=_blank style='color:#2F92EE;'>#胸膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84201, encryptionId=bbaf8420118, topicName=胸膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fbc026056217, createdName=lifestar, createdTime=Mon Jan 20 23:26:00 CST 2020, time=2020-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916090, encodeId=a14b19160905f, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Thu Feb 13 14:26:00 CST 2020, time=2020-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1579809, encodeId=f58d15e98091f, content=<a href='/topic/show?id=6db59e28738' target=_blank style='color:#2F92EE;'>#间皮瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97287, encryptionId=6db59e28738, topicName=间皮瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d61a16562641, createdName=1249884fm92暂无昵称, createdTime=Sat Mar 23 12:26:00 CST 2019, time=2019-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594579, encodeId=eaf815945e9cc, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Mar 23 12:26:00 CST 2019, time=2019-03-23, status=1, ipAttribution=)]
    2020-02-13 juliusluan78

    #III#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1666277, encodeId=67d716662e711, content=<a href='/topic/show?id=bbaf8420118' target=_blank style='color:#2F92EE;'>#胸膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84201, encryptionId=bbaf8420118, topicName=胸膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fbc026056217, createdName=lifestar, createdTime=Mon Jan 20 23:26:00 CST 2020, time=2020-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916090, encodeId=a14b19160905f, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Thu Feb 13 14:26:00 CST 2020, time=2020-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1579809, encodeId=f58d15e98091f, content=<a href='/topic/show?id=6db59e28738' target=_blank style='color:#2F92EE;'>#间皮瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97287, encryptionId=6db59e28738, topicName=间皮瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d61a16562641, createdName=1249884fm92暂无昵称, createdTime=Sat Mar 23 12:26:00 CST 2019, time=2019-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594579, encodeId=eaf815945e9cc, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Mar 23 12:26:00 CST 2019, time=2019-03-23, status=1, ipAttribution=)]
    2019-03-23 1249884fm92暂无昵称

    #间皮瘤#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1666277, encodeId=67d716662e711, content=<a href='/topic/show?id=bbaf8420118' target=_blank style='color:#2F92EE;'>#胸膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84201, encryptionId=bbaf8420118, topicName=胸膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fbc026056217, createdName=lifestar, createdTime=Mon Jan 20 23:26:00 CST 2020, time=2020-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916090, encodeId=a14b19160905f, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Thu Feb 13 14:26:00 CST 2020, time=2020-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1579809, encodeId=f58d15e98091f, content=<a href='/topic/show?id=6db59e28738' target=_blank style='color:#2F92EE;'>#间皮瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97287, encryptionId=6db59e28738, topicName=间皮瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d61a16562641, createdName=1249884fm92暂无昵称, createdTime=Sat Mar 23 12:26:00 CST 2019, time=2019-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594579, encodeId=eaf815945e9cc, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Mar 23 12:26:00 CST 2019, time=2019-03-23, status=1, ipAttribution=)]
    2019-03-23 智智灵药

    #III期#

    0

相关资讯

胸腔积液不简单 这个病因误诊率极高！

男性患者，64岁，因“左胸不适，左侧胸腔积液”第一次来院就诊，入院后经予左旋氧氟沙星、头孢曲松钠抗感染及对症支持等治疗，患者左胸不适症状缓解后出院。但出院后不久又出现左侧胸痛，呈间歇性隐痛，每次持续时间不等。7个月后，患者以“左侧胸痛半年余，伴胸闷、气促1个月余”为主诉再次入住治疗。

Lancet Oncol：沙利度胺维持治疗无益于延长恶性胸膜间皮瘤患者生存期

    在恶性胸膜间皮瘤患者中，即使采用标准化疗方案，这些患者的生存期也不长。恶性胸膜间皮瘤的生长高度依赖于血管数量和血清血管生长因子浓度。而沙利度胺具有抗血管生成活性，因此，来自阿姆斯特丹荷兰肿瘤中心的Wieneke A Buikhuisen等假设在恶性胸膜间皮瘤患者维持期的治疗中采用沙利度胺进行治疗可以改善他们的临床预后，为了验证上述假设，他们设计了相关研究并将研

Lancet Oncol：PD-1免疫治疗药物能有效治疗恶性胸膜间皮瘤 (KEYNOTE-028)

现有的称为彭博瑞珠单抗的免疫治疗药物似乎有效治疗恶性胸膜间皮瘤，这是一种罕见且侵袭性的肺癌，主要是由暴露于石棉引起的。在“柳叶刀肿瘤学”杂志上，研究人员描述了使用抗体药物对这种罕见癌症的阳性结果的第一项研究。医生检查胸部 X 光片研究结果表明，免疫治疗药物显示出对恶性胸膜间皮瘤的二线治疗有希望，这是一种由暴露于石棉导致的罕见和侵袭性肺癌。

Respir Med：恶性胸膜间皮瘤理想的二线治疗是…

2018年8月，意大利学者在《Respir Med》发表了间皮瘤二线治疗的系统评价和Meta分析

NEJM：胸膜间皮瘤早期生物标志物：fibulin-3

　　科学家们尝试寻找新的生物标志物，用来早期检出胸膜间皮瘤，并制定相应的个体化治疗策略。为此纽约大学Langone医学中心的Harvey I. Pass教授及其研究团队通过研究后发现胸膜间皮瘤患者的fibulin-3显著升高，相关研究成果发表在《新英格兰医学杂志》（NEJM）上。 　　研究人员检测了92例间皮瘤患者、136名没有癌症的石棉暴露者（胸膜间皮瘤发病与接触石棉

CD26示恶性胸膜间皮瘤（MPM）化疗反应

　　日本和美国学者近期发表于《临床癌症研究》（Clinical Cancer Research）杂志的一项研究提示，CD26表达可作为预测恶性胸膜间皮瘤（MPM）对化疗反应情况的生物标志物。 　　该研究共纳入79例MPM患者，其中73.4%的肿瘤组织细胞膜表达CD26。 　　结果显示，大部分上皮型和双相型（混合型）MPM细胞膜表达CD26，而肉瘤型缺乏CD26表达。